

RECEIVED
CENTRAL FAX CENTER


JUL 19 2007

PTO/SB/21 (04-07)


TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/724,319	
	Filing Date	November 27, 2000	
	First Named Inventor	Schenk, Dale B.	
	Art Unit	1649	
	Examiner Name	Ballard, K.A.	
Total Number of Pages in This Submission	42	Attorney Docket Number	15270J-004743US

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form (1 page, submitted in duplicate) <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (8 pages) with PTO/SB/08A Form (4 pages) and PTO/SB/08B Form (8 pages) and copies of cite nos. 886 (6 pages), 887 (7 pages), and 888 (6 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks: The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Townsend and Townsend and Crew LLP		
Signature			
Printed name	Rosemarie L. Celli		
Date	July 19, 2007	Reg. No.	42,397

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Fax No. 1-571-273-8300 on July 19, 2007.			
Signature			
Typed or printed name	Jennifer O'Brien	Date	July 19, 2007

61103749 v1

JUL 19 2007

PTO/SB/17 (07-07)

Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).**FEE TRANSMITTAL**
For FY 2007☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT (\$)** 180**Complete if Known**

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, Dale B.
Examiner Name	Ballard, K. A.
Art Unit	1649
Attorney Docket No.	15270J-004743US

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 20-1430 Deposit Account Name: Townsend and Townsend and Crew LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

	FILING FEES		SEARCH FEES		EXAMINATION FEES		
	Small Entity		Small Entity		Small Entity		
Application Type	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fees Paid (\$)
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES**Fee Description**

Each claim over 20 (including Reissues)
Each independent claim over 3 (including Reissues)
Multiple dependent claims

	Small Entity	
	Fee (\$)	Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180
Multiple Dependent Claims		
	Fee (\$)	Fee Paid (\$)

Total Claims **Extra Claims** **Fee (\$)** **Fee Paid (\$)**

-20 or HP = _____ x _____ = _____

HP = highest number of total claims paid for, if greater than 20

Indep. Claims **Extra Claims** **Fee (\$)** **Fee Paid (\$)**

-3 or HP = _____ x _____ = _____

HP = highest number of independent claims paid for, if greater than 3

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets **Extra Sheets** **Number of each additional 50 or fraction thereof** **Fee (\$)** **Fee Paid (\$)**

_____ - 100 = _____ / 50 = _____ (round up to a whole number) x _____ = _____

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Submission of Information Disclosure Stmt

Fees Paid (\$)**\$180****SUBMITTED BY**

Signature	<i>Rosemarie L. Celli</i>	Registration No. (Attorney/Agent)	42,397	Telephone	650-326-2400
Name (Print/Type)	Rosemarie L. Celli	Date	July 19, 2007		


61103738 v1

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on July 19, 2007.

PATENT
Attorney Docket No.: 15270J-004743US
Client Reference No.: 209-US-CIP5C3

TOWNSEND and TOWNSEND and CREW LLP

By:


Jennifer O'Brien

RECEIVED
CENTRAL FAX CENTER
JUL 19 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/724,319

Filed: November 27, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Ballard, K. A.

Confirmation No.: 6653

Art Unit: 1649

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of non U.S. Patent references 681-736, 738-829, 832-875, and 877-882 can be found in Application No. 09/322,289, filed May 28, 1999 (Attorney Docket No. 15270J-004740US). Copies of references 886-888 are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant also cites the following copending applications which are directed to related subject matter and are commonly owned or under an assignment obligation to be commonly owned:

07/20/2007 TL0111 00000035 201430 09724319
01 FC:1806 180.00 DA

Dale B. Schenk
Application No.: 09/724,319
Page 2

PATENT

09/201,430 filed 11/30/98; issued as U.S. 6,787,523 on 09/07/04;
09/724,477 filed 11/28/00; issued as U.S. 6,787,143 on 09/07/04;
09/723,927 filed 11/28/00; issued as U.S. 6,787,138 on 09/07/04;
09/723,762 filed 11/28/00; issued as U.S. 6,787,144 on 09/07/04;
09/724,102 filed 11/28/00; issued as U.S. 6,787,139 on 09/07/04;
09/724,489 filed 11/28/00; issued as U.S. 6,787,140 on 09/07/04;
10/816,022 filed 03/31/04; issued as U.S. 6,866,850 on 03/15/05;
10/816,529 filed 03/31/04; issued as U.S. 6,818,218 on 11/16/04;
10/815,391 filed 03/31/04; issued as U.S. 6,866,849 on 03/15/05;
10/934,818 filed 09/02/04;
11/108,102 filed 04/15/05;
11/245,524 filed 10/07/05;
10/934,609 filed 09/02/04; issued as U.S. 6,946,135 on 09/20/2005;
11/245,916 filed 10/7/05;
10/933,559 filed 09/02/04; issued as U.S. 6,972,127 on 12/06/05;
10/815,353 filed 03/31/04; issued as U.S. 6,808,712 on 10/26/04;
10/816,380 filed 03/31/04; issued as US 7,014,855 on 03/21/06;
10/815,404 filed 03/31/04; issued as U.S. 6,982,084 on 01/03/06;
10/884,892 filed 07/01/04; issued as U.S. 6,962,707 on 11/08/05;
09/322,289 filed 05/28/99;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00; issued as U.S. 6,710,226 on 03/23/04;
10/429,216 filed 05/30/03;
10/828,548 filed 04/19/04;
10/923,471 filed 08/20/04;

Dale B. Schenk
Application No.: 09/724,319
Page 3

PATENT

10/923,474 filed 08/20/04;
10/923,605 filed 08/20/04;
10/923,469 filed 08/20/04;
09/724,940 filed 11/28/00; issued as U.S. 6,905,686 on 06/14/05;
09/724,961 filed 11/28/00; issued as U.S. 6,743,427 on 6/1/04;
11/058,757 filed 02/14/05;
09/580,018 filed 05/26/00; issued as U.S. 6,761,888 on 07/13/04;
09/724,552 filed 11/28/00; issued as U.S. 6,750,324 on 6/15/04;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00; issued as U.S. 6,787,637 on 09/07/04;
09/724,288 filed 11/28/00;
10/777,792 filed 02/11/04;
10/890,000 filed 07/12/04;
10/890,071 filed 07/12/04;
09/723,765 filed 11/28/00;
09/724,567 filed 11/28/00; issued as U.S. 6,890,535 on 05/10/05;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00; issued as U.S. 6,875,434 on 04/05/05;
09/724,570 filed 11/28/00; issued as U.S. 6,936,246 on 08/30/05;
and
09/979,952 filed 04/09/02 (U.S. National Stage of PCT/US00/15239
filed 06/01/00); issued as U.S. 6,913,745 on 07/05/05.

Applicant also cites the following copending applications directed to related
subject matter but subject to different assignment:

10/010,942 filed 12/06/01; Issued as US 7,189,819 on 03/13/07;
10/789,273 filed 2/27/04;

Dale B. Schenk
Application No.: 09/724,319
Page 4

PATENT

10/232,030 filed 08/30/02;
10/388,389 filed 03/12/03; issued as US 7,179,892 on 02/20/07;
10/388,214 filed 03/12/03;
10/858,855 filed 06/01/04;
10/771,174 filed 02/04/04;
11/260,047 filed 10/26/05;
11/304,986 filed 12/15/05;
11/305,889 filed 12/15/05;
11/305,899 filed 12/15/05;
11/303,478 filed 12/15/05;
11/304,072 filed 12/15/05;
60/736,119 filed 11/10/05;
60/735,687 filed 11/10/05;
10/544,093 filed 08/01/05 (U.S. National Stage of PCT/US04/02856
filed 01/31/04);
11/342,353 filed 01/27/06;
10/583,503 filed 06/16/06
11/454,772 filed 06/16/06.
11/516,724 filed 09/05/06;
11/520,438 filed 09/12/06; and
60/793,014 filed 04/18/06.

Applicant further cites the following commonly owned abandoned applications or
abandoned applications under an assignment obligation to be commonly owned which are
directed to related subject matter:

60/067,740 filed 12/02/97;

Dale B. Schenk
Application No.: 09/724,319
Page 5

PATENT

60/080,970 filed 04/07/98;
10/928,926 filed 08/27/04;
09/580,015 filed 05/26/00;
10/889,999 filed 04/12/04;
09/580,019 filed 05/26/00;
09/724,291 filed 11/28/00;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;
09/980,568 filed 03/12/02 (U.S. National Stage of PCT/US00/15302
filed 06/01/00);
09/579,690 filed 05/26/00;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00;
09/724,929 filed 11/28/00;
60/137,010 filed 06/01/99;
60/137,047 filed 06/01/99;
60/136,655 filed 05/28/99,
09/723,544 filed 11/28/00.
09/497,553 filed 02/03/00;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,495 filed 11/27/00;

Dale B. Schenk
Application No.: 09/724,319
Page 6

PATENT

10/788,666 filed 02/27/04;

09/979,701 filed 03/13/01 (U.S. National Stage of PCT/US00/14810
filed 05/26/00);

10/822,968 filed 04/12/04;

10/823,463 filed 04/12/04;

10/890,024 filed 04/12/04;

10/890,070 filed 07/12/04;

10/923,267 filed 08/20/04;

10/934,819 filed 09/02/04; and

11/396,391 filed 03/30/2006.

Applicant also cites the following abandoned applications directed to related
subject matter but subject to different assignment:

10/703,713 filed 11/07/03;

10/704,070 filed 11/07/03;

11/396,417 filed 03/30/06;

11/413,638 filed 04/28/06;

60/251,892 filed 12/06/00;

60/444,150 filed 02/01/03;

60/616,474 filed 10/05/04;

60/530,481 filed 12/17/03;

60/474,654 filed 05/30/03;

60/363,751 filed 03/12/02.

60/622,525 filed 10/26/04;

60/636,684 filed 12/15/04;

Dale B. Schenk
Application No.: 09/724,319
Page 7

PATENT

60/636,842 filed 12/15/04;
60/637,253 filed 12/16/04;
60/636,810 filed 12/15/04;
60/637,138 filed 12/16/04;
60/636,776 filed 12/15/04;
60/636,687 filed 12/15/04;
60/736,045 filed 11/10/05;
60/691,821 filed 06/17/05; and
60/648,631 filed 01/28/05.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she are invited to call the undersigned who will be happy to supply them.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference


Dale B. Schenk
Application No.: 09/724,319
Page 8

PATENT

should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
R1C:crf:jeo

61102311 v1

JUL 19 2007

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 12

Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, D. B.
Art Unit	1849
Examiner Name	Ballard, K. A.
Attorney Docket Number	15270J-004743US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	855	7,195,761	03-27-2007	Holtzman et al.	
	878	7,189,819	03-13-2007	Basi et al.	
	879	7,179,892	02-20-2007	Basi et al.	
	880	7,014,855	03-21-2006	Schenk	
	881	6,982,084	01-03-2006	Schenk	
	686	6,972,127	12-06-2005	Schenk	
	785	2005/0249725 A1	11-10-2005	Schenk et al.	
	866	6,962,984	11-08-2005	Ishiwata et al.	
	693	2005/0191314 A1	09-01-2005	Schenk	
	713	6,936,698	08-30-2005	Taylor	
	716	6,933,368	08-23-2005	Co et al.	
	758	2005/0169925 A1	08-04-2005	Bardroff et al.	
	685	2005/0163788 A1	07-28-2005	Schenk	
	884	2005/0152878 A1	07-14-2005	Solomon et al.	
	715	2005/0136054 A1	06-23-2005	Adair et al.	
	714	2005/0123534 A1	06-09-2005	Adair et al.	
	784	2005/0118651 A1	06-02-2005	Basi et al.	
	683	2005/0059802 A1	03-17-2005	Schenk et al.	
	684	2005/0059591 A1	03-17-2005	Schenk et al.	
	805	2004/0197324 A1	10-07-2004	Jun et al.	
	882	6,787,139	09-07-2004	Schenk	
	783	2004/0087777 A1	05-06-2004	Basi et al.	
	782	2004/0082762 A1	04-29-2004	Basi et al.	
	849	6,727,349	04-27-2004	LaRosa et al.	
	870	2003/0207828 A1	11-06-2003	Ishiwata et al.	
	708	2003/0039645 A1	10-14-2003	Adair et al.	
	804	2003/0202972 A1	10-30-2003	James et al.	
	712	6,639,055	10-28-2003	Carter et al.	
	709	6,632,927	10-14-2003	Adair et al.	
	748	6,610,493	08-26-2003	Citron et al.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
61102386

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, D. B.
Art Unit	1649
Examiner Name	Ballard, K. A.
Attorney Docket Number	15270J-004743US

Sheet	2	of	12	Attorney Docket Number	15270J-004743US
	730	2003/0166557 A1		09-04-2003	Minna et al.
	869	2003/0135035 A1		07-17-2003	Shannon
	883	6,582,945		06-24-2003	Raso
	871	2003/0092145 A1		05-15-2003	Jira et al.
	702	6,548,640		04-15-2003	Winter
	725	6,538,124		03-25-2003	Idusogie et al.
	726	6,528,624		03-04-2003	Idusogie et al.
	710	6,407,213		06-18-2002	Carter et al.
	776	6,372,716		04-16-2002	Bush et al.
	720	6,277,375		08-21-2001	Ward
	777	6,270,757		08-07-2001	Warne
	778	6,267,958		07-31-2001	Andya et al.
	795	6,210,671		04-03-2001	Co
	724	6,194,551		02-27-2001	Idusogie et al.
	704	6,180,370		01-30-2001	Queen et al.
	747	6,175,057		01-16-2001	Mucke et al.
	719	6,165,745		12-26-2000	Ward et al.
	723	6,121,022		09-19-2000	Presta et al.
	711	6,054,297		04-25-2000	Carter et al.
	722	5,869,046		02-09-1999	Presta et al.
	867	5,866,129		02-02-1999	Chang et al.
	707	5,859,205		01-12-1999	Adair et al.
	860	5,858,981		01-12-1999	Schreiber et al.
	771	5,837,268		11-17-1998	Potter et al.
	885	5,798,102		08-25-1998	McMichael et al.
	779	5,770,700		06-23-1998	Webb et al.
	780	5,744,132		04-28-1998	Warne et al.
	770	5,733,548		03-31-1998	Restifo et al.
	705	5,693,761		12-02-1997	Queen et al.
	721	5,677,425		10-14-1997	Bodmer et al.
	717	5,648,260		07-15-1997	Winter et al.
	718	5,624,821		04-29-1997	Winter et al.
	764	5,601,827		02-11-1997	Collier et al.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
61102386

RECEIVED
CENTRAL FAX CENTER

JUL 19 2007

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, D. B.
				Art Unit	1649
				Examiner Name	Ballard, K. A.
Sheet	3	of	12	Attorney Docket Number	15270J-004743US

706	5,585,089	12-17-1996	Queen et al.
781	5,385,887	01-31-1995	Yim et al.
868	5,245,015	09-14-1993	Fung et al.
819	5,227,159	07-13-1993	Miller
703	5,225,539	07-06-1993	Winter
740	4,883,666	11-28-1989	Sabel et al.
691	11/245,524	filed 10-07-2005	Schenk
692	11/245,916	filed 10-07-2005	Schenk
763	60/067,740	filed 12-02-1997	Schenk
780	60/067,219	filed 12-03-1997	Weiner et al.
761	60/079,697	filed 03-27-1998	Weiner et al.
762	60/080,970	filed 01-11-1999	Schenk

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	853	EP	921 189	B1	01-12-2005			
	842	EP	1 481 992	A2, A3	12-01-2004			
	786	EP	758 901	B1	02-26-1997			
	787	EP	758 248	B1	02-19-1997			
	738	EP	626 390	A1	11-30-1994			
	802	EP	597 101	A1	05-18-1994			
	820	EP	285 159	A1	10-05-1988			
	848	WO	05/02621.1	A2, A3	03-24-2005			
	701	WO	05/014041	A2	02-17-2005			
	757	WO	04/108895	A2, A3	12-16-2004			
	847	WO	04/071408	A2	08-26-2004			
	797	WO	04/055164	A2	07-01-2004			
	846	WO	04/044204	A2, A3	05-27-2004			
	796	WO	03/105894	A1	12-24-2003			
	845	WO	03/072036	A2, A3	09-04-2003			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 61102386

RECEIVED
CENTRAL FAX CENTER

JUL 19 2007

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, D. B.
Art Unit	1649
Examiner Name	Ballard, K. A.
Attorney Docket Number	15270J-004743US

Sheet 4 of 12

799	WO	03/39485	A2	05-15-2003			
756	WO	03/16467	A2, A3	02-27-2003			
803	WO	03/16466	A2	02-27-2003			
788	WO	03/15691	A2	02-27-2003			
798	WO	03/09817	A2	02-06-2003			
827	WO	02/96937	A2	12-05-2002			
789	WO	01/05355	A2	01-25-2001			
772	WO	99/10008	A1	03-04-1999			
813	WO	97/03192	A3	01-30-1997			
854	WO	95/07301	A1	03-16-1995			
698	WO	95/06407	A1	03-09-1995			
736	WO	94/10569	A1	05-11-1994			
814	WO	94/00153	A1	01-06-1994			
821	WO	91/16928	A1	11-14-1991			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0661-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, D. B.
				Art Unit	1649
				Examiner Name	Ballard
Sheet	5	of	12	Attorney Docket Number	15270J-004743US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	773	ALBERTS ET AL., <i>Molecular Biology of the Cell, 2nd Edition</i> , pages 266-267, Garland Publishing Inc., New York (1989).	
	875	ARD et al., "Scavenging of Alzheimer's Amyloid β -Protein by Microglia in Culture," <i>J. Neuroscience Research</i> , 43:190-202 (1996).	
	681	AULD et al., "Alzheimer's disease and the basal forebrain cholinergic system: relations to β -amyloid peptides, cognition, and treatment strategies," <i>Progress in Neurobiol.</i> , 68:209-245 (2002).	
	790	BALES et al., "Administration of an Anti-A β Fab Fragment to APP ^{V717F} Transgenic Mice Reduces Neuritic Plaque," Abstract P4-396, Page S587, presented at Poster Session P4: Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based	
	858	BALES et al., "Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A β antibody," <i>J. Clin. Invest.</i> , 116(3):825-832 (2006).	
	750	BICKEL et al., "Development and in Vitro Characterization of a Cationized Monoclonal Antibody against β A4 Protein: A Potential Probe for Alzheimer's Disease," <i>Bioconjugate Chem.</i> , 5:119-125 (1994).	
	754	BLASBERG et al., "Regional Localization of Glioma-associated Antigen Defined by Monoclonal Antibody 81C8 in Vivo: Kinetics and Implications for Diagnosis and Therapy," <i>Cancer Research</i> , 47:4432-4443 (1987).	
	840	BORENSTEIN, S., "New Alzheimer's vaccine to be tested on people soon, Early experiments on mice halted condition; considered safe for humans," <i>Free Press</i> , 7/23/01.	
	746	BRAZIL et al., "Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia," <i>J. Biol. Chem.</i> , 275(22):16941-16947 (2000).	
	832	BROADWELL et al., "Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system," <i>Exp. Neurol.</i> , 120(2):245-263 (1993).	
	824	BROOKMEYER et al., "Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset," <i>Am. J. Public Health</i> , 88:1337-1342 (1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, D. B.
				Art Unit	1649
				Examiner Name	Ballard
Sheet	6	of	12	Attorney Docket Number	15270J-004743US

791	BUSSIERE et al., "Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive A β Immunotherapy on Their Clearance," <u>Am. J. Pathology</u> , 165(3):987-995 (2004).	
823	CASELL et al., "Demography and Epidemiology of Age-Associated Neuronal Impairment," chapter 4, pages 31-50 from <u>Functional Neurobiology of Aging</u> , Hof et al., eds., Academic Press (2001).	
699	CLAYTON et al., "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," <u>J. Neurosci. Res.</u> , 58:120-129 (1999).	
766	COICO et al., <u>Immunology A Short Course, Fifth Edition</u> , pages 18-24 (2003).	
859	COMERY et al., "Passive Immunization Against β -Amyloid Leads to Acute Cognition Improvement," <u>Society for Neuroscience</u> , abstract, Washington DC, 11/12-16/05.	
687	COX et al., "Adjuvants—a classification and review of their modes of action," <u>Vaccine</u> , 15(3):248-256 (1997).	
836	DAS et al., "Reduced effectiveness of A β -42 immunization in APP transgenic mice with significant amyloid deposition," <u>Neurobiology of Aging</u> , 22:721-727 (2001).	
769	DAVIS, S. S., "Nasal Vaccines," <u>Advanced Drug Delivery Reviews</u> , 51:21-42 (2001).	
861	DE FELICE et al., " β -Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease," <u>Cell Mol. Neurobiol.</u> , 22(5/6):545-563 (2002).	
689	DE LUSTIG et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations," <u>Rev. In Neurosciences</u> , 5:213-225 (1994).	
745	DEWITT et al., "Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease," <u>Experimental Neurology</u> , 149:329-340 (1998).	
698	Dictionary.com definition of "prophylactic", pages 1-3 downloaded from internet 10/12/05.	
735	DI MARTINO et al., "Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-carrier Linked Synthetic Peptide Immunogens," <u>J. Molecular Recognition</u> , 4(2-3):85-91 (1991).	
862	DISIS et al., "Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines," <u>Blood</u> , 88(1):202-210 (1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, D. B.
				Art Unit	1649
				Examiner Name	Ballard
Sheet	7	of	12	Attorney Docket Number	15270J-004743US

817	DU et al., "α ₂ -Macroglobulin as a β-Amyloid Peptide-Binding Plasma Protein," <u>J. Neurochemistry</u> , 69(1):299-305 (1997).	
811	European Search Report of 5/22/06 for European Application 06075704.4-2107.	
812	European Search REport of 5/22/06 for European Application 06075479.3-2107.	
852	European Search Report of 1/16/07 for European Application 04776252.1-2405.	
873	GEYLIS et al., "Immunotherapy of Alzheimer's disease 9AD): From murine models to anti-amyloid beta 9Ab) human monoclonal antibodies," <u>Autoimmunity Rev.</u> , 5:33-39 (2000).	
694	GUPTA et al., "Adjuvants for human vaccines—current status, problems, and future prospects," <u>Vaccine</u> , 13(14):1263-1275 (1995).	
807	HARA et al., "Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease," <u>J. Alzheimer's Disease</u> , 6:483-488 (2004).	
741	HIRSCHFIELD et al., "Amyloidosis: new strategies for treatment," <u>Int. J. Biochem. & Cell Biol.</u> , 35:1608-1613 (2003).	
887	IDUSOGIE et al., "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunology</u> , 164:4178-4184 (2000).	
792	KAJKOWSKI et al., "β-Amyloid Peptide-induced Apoptosis Regulated by a Novel Protein Containing a G Protein Activation Module," <u>J. Biol. Chem.</u> , 276(22):18748-18756 (2001).	
834	KALBACK et al., "APP Transgenic Mice Tg2576 Accumulate Aβ Peptides That Are Distinct from the Chemically Modified and Insoluble Peptides Deposited in Alzheimer's Disease Senile Plaques," <u>Biochemistry</u> , 41:922-928 (2002).	
729	KASCSAK et al., "Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins," <u>J. Virology</u> , 61(12):3688-3693 (1987).	
863	KIMCHI et al., "Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using in vivo multiphoton microscopy," <u>J. Neuropath Exp. Neurol.</u> , 60(3):274-279 (2001).	
843	KLYUBIN et al., "Anti-Aβ Antibodies Prevent Block of Long-Term Potentiation In the CA1 Area of Rat Hippocampus <i>InVivo</i> by naturally Produced Aβ Oligomers," <u>Neurobiology of Aging</u> , 25:S224-S225, abstract P2-004, pages S224-S225 (2004).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

RECEIVED
CENTRAL FAX CENTER

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, D. B.
				Art Unit	1649
				Examiner Name	Ballard
Sheet	8	of	12	Attorney Docket Number	15270J-004743US

794	KOFLER et al., "Immunoglobulin κ Light Chain Variable Region Gene Complex Organization and Immunoglobulin Genes Encoding Anti-DNA Autoantibodies in Lupus Mice," <u>J. Clin. Invest.</u> , 82:852-860 (1988).	
826	KUBY, J., eds., page 123 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).	
888	KUBY, J., eds., pages 108-109, 131-132 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).	
695	KUO et al., "Water-soluble A β (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," <u>J. Biol. Chem.</u> , 271(8):4077-4081 (1996).	
833	KUO et al., "Comparative Analysis of Amyloid- β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains," <u>J. Biol. Chem.</u> , 276(16):12991-12998 (2001).	
734	KURASHIMA et al., "Production of Monoclonal Antibody against Amyloid Fibril Protein and Its Immunohistochemical Application," <u>Appl. Pathol.</u> , 3(1-2):39-54 (1985).	
816	LaDu et al., "Isoform-specific Binding of Apolipoprotein E to β -Amyloid," <u>J. Biol. Chem.</u> , 269(38):23403-23406 (1994).	
755	LAVIE et al., "EFRH-Phage Immunization of Alzheimer's Disease Animal Model Improves Behavioral Performance in Morris Water Maze Trials," <u>J. Molecular Neuroscience</u> , 24:105-113 (2004).	
743	LICASTRO et al., "Is Immunotherapy an effective treatment for Alzheimer's disease?," <u>Immunity & Aging</u> , 1:1-2 (2004).	
727	LINKE, "Monoclonal antibodies against amyloid fibril protein AA. Production, specificity, and use for immunohistochemical localization and classification of AA-type amyloidosis," <u>J. Histochemistry and Cytochemistry</u> , 32(3):322-328 (1982).	
742	MANOJ et al., "Approaches to Enhance the Efficacy of DNA Vaccines," <u>Critical Rev. Clin. Lab. Sci.</u> , 41(1):1-39 (2004).	
731	MARHAUG et al., "Monoclonal hybridoma antibodies to human amyloid related protein SAA," <u>Clin. Exp. Immunol.</u> , 50(2):390-396 (1982).	
744	MAROTTA et al., "Overexpression of amyloid precursor protein A4 (β -amyloid) immunoreactivity in genetically transformed cells: Implications for a cellular model of Alzheimer amyloidosis," <u>PNAS</u> , 86:337-341 (1989).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, D. B.
				Art Unit	1649
				Examiner Name	Ballard
Sheet	9	of	12	Attorney Docket Number	15270J-004743US

732	MAURY et al., "Immunohistochemical Localization of Amyloid in Finnish Hereditary Amyloidosis with Antibodies to Gelsolin Peptides," <u>Laboratory Investigation</u> , 64(3):400-404 (1991).	
822	Merriam-Webster online medical dictionary, entry for "cure", accessed September 5, 2006.	
886	MORGAN et al., "The N-terminal end of the C _H 2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcγRII and FcγRIII binding," <u>Immunology</u> , 86:319-324 (1995).	
841	OKIE, S., "Promising Vaccine Targets Ravager of Minds," <u>Washington Post</u> , page A01, 5/8/01.	
808	OKURA et al., "Nonviral Aβ DNA vaccine therapy against Alzheimer's disease: Long-term effect and safety," <u>PNAS</u> , 103(25):9619-9624 (2006).	
829	PARDRIDGE et al., "The Blood-Brain Barrier: Bottleneck in Brain Drug Development," <u>J. Am. Soc. Exp. Neurotherapeutics</u> , 2:3-14 (2005).	
682	PARNETTI et al., "Cognitive Enhancement Therapy for Alzheimer's Disease, The Way Forward," <u>Drugs</u> , 53(5):752-768 (1997).	
806	PCT Search Report of 8/11/06 for application PCT/US2006/002837.	
850	PCT Search Report of 8/8/06 for application PCT/US2005/045515.	
872	PCT Search Report of 4/6/06 and Written Opinion of 4/8/06 for application PCT/US04/44093.	
774	PEETERS et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates," <u>J. Immunological Methods</u> , 120:133-143 (1989).	
733	PHELPS et al., "Development and Characterization of Monoclonal Antibodies Specific for Amylin," <u>Hybridoma</u> , 15(5):379-386 (1996).	
864	PIERA et al., "Cytokines as adjuvants: effects on the immunogenicity of NeuAc alpha 2-GalNAc alpha-O-Ser/Thr (sialyl-Tn)," <u>Int. J. Cancer</u> , 55(1):148-152 (1993).	
837	Press Release, "Alzheimer's vaccine developer awarded Potamkin Prize," American Academy of Neurology, 5/7/01.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, D. B.
				Art Unit	1649
				Examiner Name	Ballard
Sheet	10	of	12	Attorney Docket Number	15270J-004743US

751	PROBERT et al., "Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α ," <u>PNAS</u> , 92:11294-11298 (1995).	
809	QU et al., "A β ₄₂ gene vaccination reduces brain amyloid plaque burden in transgenic mice," <u>J. Neurological Sciences</u> , 244:151-158 (2006).	
838	ROSENBERG, R. N., "The Potamkin Prize for Pick's, Alzheimer's Disease and Related Disorders," pages 1-5.	
865	ROSES, A.D., "Apoplipoprotein E alleles as risk factors in Alzheimer's disease," <u>Annu. Rev. Med.</u> , 47:387-400 (1996).	
851	SALDANHA et al., "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," <u>Molecular Immunology</u> , 36:709-719 (1999).	
759	SCHENK et al., "Current progress in beta-amyloid immunotherapy," <u>Curr. Opin. Immunology</u> , 16(5):599-606 (2004).	
768	SCHMITT et al., "Interactions of the alzheimer β amyloid fragment ₍₂₅₋₃₅₎ with peripheral blood dendritic cells," <u>Mechanisms of Ageing and Development</u> , 94:223-232 (1997).	
856	SEUBERT et al., "Antibody Capture of Soluble A β does not Reduce Cortical A β Amyloidosis in the PDAPP Mouse," <u>Neurodegenerative Diseases</u> , (2007).	
818	SHINKAI et al., "Amyloid β -Proteins 1-40 and 1-42(43) in the Soluble Fraction of Extra- and Intracranial Blood Vessels," <u>Ann. Neurol.</u> , 38:421-428 (1995).	
828	Signet Laboratories, Inc., Product data sheet for mouse monoclonal clone 6E10, revised 7/13/05.	
697	SMALL et al., "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <u>PNAS</u> , 97(11):6037-6042 (2000).	
874	SOTO et al., "The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis," <u>Biochem. J.</u> , 314:701-707 (1996).	
839	TRAVIS, J., "A Vaccine for Alzheimer's Disease?®," <u>Science News Online</u> , 156(2) pages 1-3 downloaded from internet (1999).	
857	TRAVIS, J., "Saving the Mind Faces High Hurdles," <u>Science</u> , 309:731-734 (2005).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0661-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, D. B.
				Art Unit	1649
				Examiner Name	Ballard
				Attorney Docket Number	15270J-004743US
(use as many sheets as necessary)					
Sheet	11	of	12		

767	TRIEB et al., "APP Peptides Stimulate Lymphocyte Proliferation in Normals, But Not in Patients With Alzheimer's Disease," <u>Neurobiology of Aging</u> , 17(4):541-547 (1996).	
844	UniProtKB/Swiss-Prot entry P18525, pages 1-3 downloaded from http://www.expasy.org/cgi-bin/niceprot.pl/printable?ac=P18525 on 2/8/97, "HV54_Mouse" (11/1/90).	
815	URMONEIT et al., "Cerebrovascular Smooth Muscle Cells Internalize Alzheimer Amyloid Beta Protein via a Lipoprotein Pathway: Implications for Cerebral Amyloid Angiopathy," <u>Laboratory Investigation</u> , 77(2):157-166 (1997).	
700	VALLEIX et al., "Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family," <u>Kidney International</u> , 61:907-912 (2002).	
775	VAN DEN DOBBELSTEEN et al., "Characteristics of Immune Responses to Native and Protein Conjugated Pneumococcal Polysaccharide Type 14," <u>Scand. J. Immunol.</u> , 41:273-280 (1995).	
835	VAN LEUVEN, F., "Single and multiple transgenic mice as models for Alzheimer's disease," <u>Progress in Neurobiology</u> , 61:305-312 (2000).	
690	VICKERS, J. C., "A Vaccine Against Alzheimer's Disease," <u>Drugs Aging</u> , 19(7):487-494 (2002).	
800	VIDANOVIC et al., "Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation," <u>DIE PHARMAZIE</u> , 58(6):399-404 (2003).	
801	WANG, W., "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <u>Int. J. Pharmaceutics</u> , 185(2):129-188 (1999).	
688	<u>Webster's New World Dictionary of American English</u> , Third College Edition, page 1078 (1988).	
749	Wikipedia definition of "epitope" printed from internet on 4/26/06.	
752	Wikipedia definition of "antigen" printed from internet on 4/26/06.	
753	Wikipedia definition of "route of administration including parenteral" printed from internet on 4/26/06.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386

JUL 19 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 12 of 12

Complete If Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, D. B.
Art Unit	1649
Examiner Name	Ballard
Attorney Docket Number	15270J-004743US

728	YAMADA et al., "Generation and Characterization of Rat Monoclonal Antibodies Against Human Serum Amyloid A," <u>Scand. J. Immunol.</u> , 46(2):175-179 (1997).
793	ZAMEER et al., "Single Chain Fv Antibodies against 25-35 Peptide Fragment of Amyloid- β : Potential Therapeutic for Alzheimer's Disease," Abstract P4-420, Page S593, presented at Poster Session P4:Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based
825	ZHANG et al., "Specialized Applications, Purification of Recombinant Proteins and Study of Protein Interaction by Epitope Tagging," <u>Current Protocols in Mol. Biol.</u> , Supp 41, pages 10.15.1 through 10.15.9 (1998).
810	ZHANG et al., "A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β -amyloid plaques in a mouse model of Alzheimer's disease," <u>Neurobiology of Disease</u> , 14:365-379 (2003).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61102386